Video
Dr. Higano on Radium-223 for mCRPC
Author(s):
Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).
Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).
Higano says radium-223 (Xofigo), a radium isotope approved by the FDA to treat mCRPC, is unique from other therapies in cancer overall. Results from a phase III study showed that patients who received radium-223 had higher overall survival (OS) compared to patients who did not receive the therapy.
Radium-223 can also benefit patients who may have skeletal metastases, fractures, or require external beam radiation, Higano says.
Radium-223 is an exciting new tool and researchers are exploring how it can be used with other novel therapies that have been developed in the last few years.
